Oryzon Genomics S.A. (OTCMKTS:ORYZF) was moving in a range after the clinical biopharmaceutical firm leveraging epigenetics to create treatments with unmet medical needs released positive efficacy findings from the current Phase IIa ALICE study.
Latest News
The trial evaluates a combination of iadademstat and azacitidine in unfit or elderly patients with acute myeloid leukemia. The company presented the data at the 63rd Annual American Society of Hematology Conference 2021.
There is robust clinical efficacy evidence that is consistent with past reported data with an ORR of 78%. Of the 27 evaluable patients, 62% showed complete remissions and 38% partial remission.It is vital to point out that the traditional ORR in unfit and elderly AML patients receive azacitidine alone. Also,important to note is that among AML groups of individuals with M5b AML and all individuals with TP53-mutant AML attained CR/Cri. Median Time to Response has been fast in 2 cycles.Therefore, ORYZF is worth watching.
